Interview with Omar Ehsan, General Manager, IMS Health South Africa
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
Address: South Wing, The Place, 1 Sandton Drive, Sandton, 2196
P O Box 784746, Sandton City, Sandton, 2146 ,South Africa
Tel: (+27-11) 783 0104
Web: http://www.drreddys.com/southafrica/
Dr. Reddy’s – South Africa operation is a wholly-owned subsidiary and one of the leading generics players in the country. With a dedicated field force it focuses on key therapeutic areas like Central Nervous System (CNS) and Primary Care.
The business performance in South Africa has been phenomenal in the last few years. The overall revenue as per FY10 has been at $9.4 million enlisting a 56% growth.
Its advantageous position is ensured through the presence of key contributors in its business model. The Research & Development capability helps the company ensure enhanced FTL Opportunities through non-infringing pdts and supports differentiation with products and competitors. Alongside, the in-house API manufacturing capabilities assures cost competitiveness in both private and tender based markets. The company’s Formulation capabilities and strong business development team ensures high-quality in-house product pipeline, shapes licensing strategy to maximize market share and enrich the product basket. All the more its committed filed force has also been promising in recent years while reaching to all segments of the market.
In the South Africa Generic market Dr. Reddy’s is ranked 18th in terms of Value and 20th in terms of volume (Source: IMS-SA IGMS, MAT, Nov. 2010).
Top-five products including Omez, Cifloc, Citraz, Amlate and DRL-Moxifloxacin contribute to over 50% of revenue.
Products cathegories:
Active Pharma Ingredients (API)
Custom Pharma Services (CPS)
Global Generics
New Chemical Entities (NCEs)
Differentiated Formulations
Biosimilars
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
In 2010, South Africa officially joined the BRICS grouping. The Indian and Russian work environments are familiar to you, considering your significant experience in these countries. How would you compare…
Ms Beaumont, can you describe the association to our readers and its main objectives? Innovative Medicines South Africa (IMSA) represents manufacturers of research-based medicines, ie they market the products of…
See our Cookie Privacy Policy Here